---
title: "Oragenics (OGEN) news: reverse split, offering and Nasdaq notice"
url: "https://aibio.space/companies/oragenics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "OGEN reverse split, offering, Nasdaq notice and settlement news: Oragenics names John Spencer CFO and reports annual meeting votes. Oragenics Inc."
---

OGEN Oragenics Inc. AMEX · United States

# Oragenics (OGEN) news OGEN reverse split, offering and Nasdaq notice news

Listings · 2026-08-28

## [Oragenics receives NYSE American deficiency letter on equity](https://aibio.space/news/oragenics-receives-nyse-american-deficiency-letter-equity/)

NYSE American notified Oragenics on August 26, 2026 that it is not in compliance with two continued listing standards on stockholders' equity. The company has 45 days to submit a compliance plan and says it intends to do so.

## Latest Oragenics news

1. 2026-07-06 Listings [Oragenics names John Spencer CFO and reports annual meeting votes](https://aibio.space/news/oragenics-names-john-spencer-cfo-reports-annual-meeting-votes/) Oragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.
2. 2026-05-07 Company Updates [Oragenics signs letter of intent to license CardioDialysis for TBI](https://aibio.space/news/oragenics-signs-letter-intent-license-cardiodialysis-tbi/) Oragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.
3. 2026-04-13 Company Updates [Oragenics doses first patient in Phase IIa concussion trial](https://aibio.space/news/oragenics-doses-first-patient-phase-iia-concussion-trial/) The first patient in the Phase IIa trial of ONP-002 was dosed at Mackay Hospital in Australia, the first site activated, with two more Australian sites expected to activate in the second quarter.
4. 2025-10-21 Listings [Oragenics regains NYSE American equity compliance, settles Ladenburg fee claim for $700,000](https://aibio.space/news/oragenics-regains-nyse-american-equity-compliance-settles-ladenburg/) NYSE American told Oragenics on October 20, 2025 that it again meets stockholders' equity standards. The company also paid Ladenburg Thalmann $700,000 to settle a dispute over a $2,500,000 fee claim.
5. 2025-08-11 Financings [Oragenics says Series H preferred raise brought $16.5 million in gross proceeds](https://aibio.space/news/oragenics-says-series-h-preferred-raise-brought-16-5-million-gross/) Net proceeds were about $15.2 million after fees and expenses. The company plans to start a Phase IIa concussion trial in Q3 2025.
6. 2025-07-02 Financings [Oragenics closes public offering of Series H preferred with about $16.5 million gross proceeds](https://aibio.space/news/oragenics-closes-public-offering-series-h-preferred-about-16-5-million/) Oragenics closed a registered offering of 660,000 Series H preferred shares and warrants on July 2, 2025, for about $16.5 million gross. The preferred converts at $2.50 a share, the conversion price has no floor, and Dawson James Securities took 7.00% of gross proceeds as placement agent.

## Oragenics at a glance

- **Ticker**: OGEN

- **Listing**: AMEX

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.9 million

### Related companies

- [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) NASDAQ: SYRE
- [Integrated BioPharma](https://aibio.space/companies/integrated-biopharma/) OTC: INBP
- [Grace Therapeutics](https://aibio.space/companies/grace-therapeutics/) NASDAQ: GRCE
- [Zeo ScientifiX](https://aibio.space/companies/zeo-scientifix/) OTC: ZEOX
- [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS
- [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) NASDAQ: PBYI
- [NanoViricides](https://aibio.space/companies/nanoviricides/) AMEX: NNVC
- [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) OTC: ZVSA

### Also on AMEX

- [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) PTHS
- [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) APUS
- [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) NSRX
- [China Pharma Holdings](https://aibio.space/companies/china-pharma/) CPHI
- [OS Therapies](https://aibio.space/companies/os-therapies/) OSTX
- [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) ARMP

## Oragenics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) |
| Net income (loss) | [-$9.8 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) |
| Cash from operations | [-$9.2 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) | [-$8.6 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) |
| Cash and equivalents | [$4.4 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226037749/) | [$864,840](https://www.sec.gov/Archives/edgar/data/1174940/000149315226010282/) |
| Short-term investments | [$4.0 million](https://www.sec.gov/Archives/edgar/data/1174940/000149315226037749/) |  |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Oragenics

Did Oragenics do a reverse stock split?

Our latest story on this, dated Jul 6, 2026: "Oragenics names John Spencer CFO and reports annual meeting votes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oragenics-names-john-spencer-cfo-reports-annual-meeting-votes/).

Has Oragenics raised money recently?

Our latest story on this, dated Jul 2, 2025: "Oragenics closes public offering of Series H preferred with about $16.5 million gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oragenics-closes-public-offering-series-h-preferred-about-16-5-million/).

Has Oragenics received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 28, 2026: "Oragenics receives NYSE American deficiency letter on equity". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oragenics-receives-nyse-american-deficiency-letter-equity/).

Has Oragenics settled a lawsuit?

Our latest story on this, dated Oct 21, 2025: "Oragenics regains NYSE American equity compliance, settles Ladenburg fee claim for $700,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oragenics-regains-nyse-american-equity-compliance-settles-ladenburg/).

What is the ticker symbol of Oragenics?

Oragenics Inc. trades under the ticker OGEN on AMEX.

Where is Oragenics listed?

Oragenics Inc. is listed on AMEX.

What is the SEC CIK of Oragenics?

The SEC Central Index Key (CIK) for Oragenics Inc. is 1174940. Its filings are on SEC EDGAR.

How many shares does Oragenics have outstanding?

4,511,957 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Oragenics listed under?

Our directory records Oragenics Inc. under United States.

What does Oragenics do?

Our directory classifies Oragenics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Oragenics?

The ISIN recorded for Oragenics Inc. is US6840236094.

Does aibio.space cover Oragenics?

aibio.space lists Oragenics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Oragenics incorporated?

SEC records list its state or country of incorporation as FL.

Is Oragenics profitable?

Oragenics Inc. reported a net loss of $9.8 million for the fiscal year ended Dec 31, 2025, and used $9.2 million of cash in operations, per its annual report to the SEC.

How much does Oragenics spend on research and development?

$2.4 million in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: Oragenics

Members talk about Oragenics (OGEN). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Oragenics, newest first. Each line links the filing it comes from.

1. 2026-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315226040645/ex99-1.htm)
2. 2026-07-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 1.01,5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315226032155/form8-k.htm)
3. 2026-05-20 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315226024602/formdef14a.htm)
4. 2026-05-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315226021969/formpre14a.htm)
5. 2026-01-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315226003237/form8-k.htm)
6. 2025-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/ex99-1.htm)
7. 2025-10-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315225018725/ex99-1.htm)
8. 2025-08-11 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/ex99-1.htm)
9. 2025-06-23 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000164117225015984/forms-1.htm)
10. 2025-05-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000164117225012596/ex99-1.htm)
11. 2025-05-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 1.01,5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000164117225008389/form8-k.htm)
12. 2025-04-01 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000164117225002090/formdef14a.htm)
13. 2025-03-27 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/ex99-1.htm)
14. 2025-03-19 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315225010918/formpre14a.htm)
15. 2025-03-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315225010389/form10-k.htm)
16. 2024-12-18 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315224050649/forms-1.htm)
17. 2024-11-29 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1174940/000149315224048190/form8-k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:OGEN on TradingView](https://www.tradingview.com/symbols/AMEX-OGEN/).

## SEC filings and registration

- **SEC name**: Oragenics Inc

- **CIK**: 1174940

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: OGEN (NYSE)

- **State or country of incorporation**: FL

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 9015 TOWN CENTER PARKWAY, LAKEWOOD RANCH, FL, 34202

- **Phone**: 8132867900

- **Shares outstanding**: 4,511,957 as of 2026-08-12 (10-Q filed 2026-08-13)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1174940/000149315226042843/form8-k.htm) filed 2026-09-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1174940/000149315226040645/form8-k.htm) filed 2026-08-28
- [10-Q](https://www.sec.gov/Archives/edgar/data/1174940/000149315226037749/form10-q.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1174940/000149315226032155/form8-k.htm) filed 2026-07-06
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1174940/000149315226024602/formdef14a.htm) filed 2026-05-20
- [8-K](https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/form8-k.htm) filed 2026-05-19
- [10-Q](https://www.sec.gov/Archives/edgar/data/1174940/000149315226021967/form10-q.htm) filed 2026-05-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/form8-k.htm) filed 2026-05-07

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001174940), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Oragenics Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker OGEN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Oragenics Inc.

- **Ticker**: OGEN

- **Listing**: AMEX

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US6840236094

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-OGEN/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/oragenics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oragenics (OGEN) news: reverse split, offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/oragenics/